Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide

Drug Discovery Today

Volumn 20, Issue 7, 2015, Pages 899-905

  Messaoudi, Khaled ^a,b   Clavreul, Anne ^a,b   Lagarce, Frédéric ^a,b,c  

^a GEROM Groupe Etudes Remodelage Osseux et BioMatériaux LHEA Laboratoire d'Histologie Embryologie LUNAM Université   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; TUMOR MARKER;

ARTICLE; CANCER RESISTANCE; DNA REPAIR; DRUG MECHANISM; DRUG STRUCTURE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; MISMATCH REPAIR; NONHUMAN; PHENOTYPE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DACARBAZINE; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; MOLECULAR STRUCTURE; PHENOTYPE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84936845832     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.02.011     Document Type: Review

References (80)

1. R. Stupp Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996
2. F. Lefranc Present and potential future issues in glioblastoma treatment Expert Rev. Anticancer Ther. 6 2006 719 732
3. F. Lefranc Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas Oncologist 12 2007 1395 1403
4. R. Stupp Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
5. 6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53 J. Med. Chem. 56 2013 7120 7132
6. H.S. Friedman Temozolomide and treatment of malignant glioma Clin. Cancer Res. 6 2000 2585 2597
7. F. Drablos Alkylation damage in DNA and RNA-repair mechanisms and medical significance DNA Repair 3 2004 1389 1407
8. J. Zhang Temozolomide: mechanisms of action, repair and resistance Curr. Mol. Pharmacol. 5 2012 102 114
9. B. Kaina MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents DNA Repair 6 2007 1079 1099
10. C.K. Park The changes in MGMT promoter methylation status in initial and recurrent glioblastomas Transl. Oncol. 5 2012 393 397
11. 6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy DNA Repair 6 2007 1100 1115
12. M. Xu-Welliver, and A.E. Pegg Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase Carcinogenesis 23 2002 823 830
13. M. Esteller Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N. Engl. J. Med. 343 2000 1350 1354
14. 6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration Carcinogenesis 24 2003 1337 1345
15. J.R. Silber O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems Biochim. Biophys. Acta 1826 2012 71 82
16. M.E. Hegi MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 352 2005 997 1003
17. B. Kaina Targeting O(6)-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy Cell Mol. Life Sci. 67 2010 3663 3681
18. 6-Methylguanine-DNA methyltransferase inactivation and chemotherapy Br. Med. Bull. 85 2008 17 33
19. W.K. Hansen, and M.R. Kelley Review of mammalian DNA repair and translational implications J. Pharmacol. Exp. Ther. 295 2000 1 9
20. D. Fu Balancing repair and tolerance of DNA damage caused by alkylating agents Nat. Rev. Cancer 12 2012 104 120
21. L. Liu Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea Cancer Res. 56 1996 5375 5379
22. S. Yip MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance Clin. Cancer Res. 15 2009 4622 4629
23. K.H. Almeida, and R.W. Sobol A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification DNA Repair 6 2007 695 711
24. R.D. Wood Human DNA repair genes Science 291 2001 1284 1289
25. M. Malanga, and F.R. Althaus The role of poly(ADP-ribose) in the DNA damage signaling network Biochem. Cell Biol. 83 2005 354 364
26. B.J. Denny NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA Biochemistry 33 1994 9045 9051
27. J.K. Horton, and S.H. Wilson Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency DNA Repair 6 2007 530 543
28. J.A. Munoz-Gamez Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles Liver Int. 2014 10.1111/liv.12586
29. P.H. Huang Oncogenic EGFR signaling networks in glioma Sci. Signal. 2 2009 re6
30. A. Guha Proliferation of human malignant astrocytomas is dependent on Ras activation Oncogene 15 1997 2755 2765
31. Y. Narita Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas Cancer Res. 62 2002 6764 6769
32. S. Furuta Ras is involved in the negative control of autophagy through the class I PI3-kinase Oncogene 23 2004 3898 3904
33. A.J. Ekstrand Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo Cancer Res. 51 1991 2164 2172
34. H.W. Lo EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance Curr. Mol. Pharmacol. 3 2010 37 52
35. L.M. Weiner Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 10 2010 317 327
36. B. Neyns Stratified Phase II trial of cetuximab in patients with recurrent high-grade glioma Ann. Oncol. 20 2009 1596 1603
37. S.E. Combs Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - Phase I/II trial: study protocol BMC Cancer 6 2006 133
38. A.A. Brandes Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments Clin. Cancer Res. 14 2008 957 960
39. P.D. Brown Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J. Clin. Oncol. 26 2008 5603 5609
40. M.D. Prados Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J. Clin. Oncol. 27 2009 579 584
41. A. Chakravarti RTOG 0211: a Phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients Int. J. Radiat. Oncol. Biol. Phys. 85 2013 1206 1211
42. J.H. Uhm Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074 Int. J. Radiat. Oncol. Biol. Phys. 80 2011 347 353
43. F.T. Liu, and G.A. Rabinovich Galectins as modulators of tumour progression Nat. Rev. Cancer 5 2005 29 41
44. I. Camby Galectin-1: a small protein with major functions Glycobiology 16 2006 137 157R
45. T. Verschuere Galectin-1 and immunotherapy for brain cancer Expert Rev. Neurother. 11 2011 533 543
46. Q.T. Le Galectin-1: a link between tumor hypoxia and tumor immune privilege J. Clin. Oncol. 23 2005 8932 8941
47. I. Camby Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern Biochem. Biophys. Res. Commun. 335 2005 27 35
48. G.A. Rabinovich Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23 2002 313 320
49. M. Le Mercier Galectins and gliomas Brain Pathol. 20 2010 17 27
50. M. Le Mercier Evidence of galectin-1 involvement in glioma chemoresistance Toxicol. Appl. Pharmacol. 229 2008 172 183
51. A. Paz Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation Oncogene 20 2001 7486 7493
52. N. Rubinstein Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege Cancer Cell 5 2004 241 251
53. G.A. Rabinovich Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis Glycobiology 16 2006 210 220
54. M.C. Miller The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain Glycobiology 19 2009 1034 1045
55. J.S. Fridman, and S.W. Lowe Control of apoptosis by p53 Oncogene 22 2003 9030 9040
56. S. Shangary, and S. Wang Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Annu. Rev. Pharmacol. Toxicol. 49 2009 223 241
57. A. Petitjean TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 26 2007 2157 2165
58. D.A. Freedman Functions of the MDM2 oncoprotein Cell. Mol. Life Sci. 55 1999 96 107
59. E.C. Burton Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors Clin. Cancer Res. 8 2002 180 187
60. K. Shchors Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy Proc. Natl. Acad. Sci. U. S. A. 110 2013 E1480 E1489
61. B. Hong Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities Curr. Drug Targets 15 2014 80 89
62. J.X. Zhu Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection Zhonghua Zhong Liu Za Zhi 32 2010 709 712
63. A.L. Wang Expression and significance of p53 protein and MDM-2 protein in human gliomas Chin. Med. J. 124 2011 2530 2533
64. L.T. Vassilev In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
65. I. Ringshausen Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo Cancer Cell 10 2006 501 514
66. H. Kato Functional evaluation of p53 and PTEN gene mutations in gliomas Clin. Cancer Res. 6 2000 3937 3943
67. C.B. Knobbe PTEN signaling in gliomas Neuro-Oncology 4 2002 196 211
68. L.D. Mayo PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy J. Biol. Chem. 277 2002 5484 5489
69. V. Stambolic Regulation of PTEN transcription by p53 Mol. Cell 8 2001 317 325
70. D.J. Freeman PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms Cancer Cell 3 2003 117 130
71. M. Tanaka MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells Oncogene 19 2000 5406 5412
72. S. Babashah, and M. Soleimani The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis Eur. J. Cancer 47 2011 1127 1137
73. M. Mizoguchi Clinical implications of microRNAs in human glioblastoma Front. Oncol. 3 2013 19
74. L. Shi MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity Brain Res. 1352 2010 255 264
75. K. Ujifuku miR-195, miR-455-3p and miR-10a(∗) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells Cancer Lett. 296 2010 241 248
76. Y.P. Yang Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI Biomaterials 33 2012 1462 1476
77. M.S. Ebert MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells Nat. Methods 4 2007 721 726
78. C.C. Esau Inhibition of microRNA with antisense oligonucleotides Methods 44 2008 55 60
79. J.C. Pang Oncogenic role of microRNAs in brain tumors Acta Neuropathol. 117 2009 599 611
80. A.A. Klyosov DAVANAT® (GM-CT-01) and colon cancer: preclinical and clinical (Phase I and II) studies A.A. Klyosov, Glycobiology and Drug Design Vol. 1102 2012 American Chemical Society 89 130